Zontivity
Drug - Zontivity™ (voraxapar) [Merck Sharp & Dohme Corp]
November 2014
Therapeutic Area - Platelet aggregation inhibitors
Approval criteria
- Patient must have a history of myocardial infarction or peripheral artery disease AND
- Patient must also be taking concurrent therapy with aspirin or clopidogrel AND
- Patient has no previous medical history of stroke, TIA or intracranial hemorrhage
Questions?
MHCP Provider Call Center 651-431-2700 or 800-366-5411